Aspirin and colorectal cancer: the promise of precision chemoprevention
暂无分享,去创建一个
Yin Cao | Andrew T. Chan | David A. Drew | D. Drew | Yin Cao | A. Chan
[1] Steven Gallinger,et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 , 2007, Nature Genetics.
[2] A. Zauber,et al. The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma , 2011, Cancer Prevention Research.
[3] L. Marton,et al. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases , 2007, Nature Reviews Drug Discovery.
[4] R. Morgenstern,et al. Microsomal glutathione transferase 1: mechanism and functional roles , 2011, Drug metabolism reviews.
[5] N. Habermann,et al. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. , 2014, Carcinogenesis.
[6] Rodney J Scott,et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.
[7] D. Schaid,et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. , 2001, American journal of human genetics.
[8] V. Fuster,et al. Aspirin: A Historical and Contemporary Therapeutic Overview , 2011, Circulation.
[9] T. Yeatman,et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation , 2015, Acta oncologica.
[10] J. Manson,et al. Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study , 1998, Annals of Internal Medicine.
[11] A. Tenesa,et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer , 2010, Gut.
[12] Gianni Tognoni,et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.
[13] Patrick T. Bradshaw,et al. Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS) , 2015, Cancer Prevention Research.
[14] C Warlow,et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[15] M. Bertagnolli,et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors , 2009, Proceedings of the National Academy of Sciences.
[16] E. Gerner,et al. Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.
[17] N. Rifai,et al. Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies , 2015, Cancer Causes & Control.
[18] D. Cameron,et al. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours , 2016, Contemporary clinical trials.
[19] T. Willson,et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[20] Enrique Casado,et al. PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.
[21] C. Hutter,et al. Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants , 2015 .
[22] Jo-Fen Liu,et al. Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention , 2008, Clinical Cancer Research.
[23] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[24] P. Rothwell,et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.
[25] M. Thun,et al. The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.
[26] S. Narumiya,et al. Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. , 2015, Cancer research.
[27] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[28] X. Ye,et al. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies , 2014, British Journal of Cancer.
[29] P. Kuppen,et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. , 2014, JAMA internal medicine.
[30] E. E. Gresch. Genetic Alterations During Colorectal-Tumor Development , 1989 .
[31] Jo-Fen Liu,et al. Polymorphisms in PTGS1, PTGS2 and IL‐10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial , 2007, International journal of cancer.
[32] S. Narumiya,et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.
[33] D. Buist,et al. Aspirin Use for the Prevention of Colorectal Cancer , 2015 .
[34] C. Ulrich,et al. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment , 2012, Cancer Causes & Control.
[35] Jeannette Bigler,et al. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.
[36] M. Thun,et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.
[37] G. Beck,et al. A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.
[38] A. Algra,et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.
[39] S. Baek,et al. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. , 2013, Biochemical pharmacology.
[40] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[41] Feng Yang,et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2009, The New England journal of medicine.
[42] D. Dixon,et al. Mechanistic aspects of COX-2 expression in colorectal neoplasia. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[43] C. Carlson,et al. Genetic Variation in Prostaglandin E2 Synthesis and Signaling, Prostaglandin Dehydrogenase, and the Risk of Colorectal Adenoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[44] J. Morrow,et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. , 2006, The Journal of clinical investigation.
[45] E. Giovannucci,et al. Urinary PGE-M Levels Are Associated with Risk of Colorectal Adenomas and Chemopreventive Response to Anti-Inflammatory Drugs , 2014, Cancer Prevention Research.
[46] D. Kerr,et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Zauber,et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. , 2009, Gastroenterology.
[48] Y. Collan,et al. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. , 2013, Anticancer research.
[49] M. Hull. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? , 2005, European journal of cancer.
[50] G. Meijer,et al. Serrated neoplasia—role in colorectal carcinogenesis and clinical implications , 2015, Nature Reviews Gastroenterology &Hepatology.
[51] A. Neugut,et al. Recurrence rates for colorectal polyps , 1985, Cancer.
[52] B C Morson,et al. The evolution of colorectal carcinoma. , 1984, Clinical radiology.
[53] Han Wu,et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis , 2014, Gut.
[54] E. Giovannucci,et al. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men , 2013, British Journal of Cancer.
[55] E. Whitlock,et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms , 2015 .
[56] R. DuBois,et al. Eicosanoids and cancer , 2010, Nature Reviews Cancer.
[57] J. Baron,et al. Cyclooxygenase-2 Polymorphisms, Aspirin Treatment, and Risk for Colorectal Adenoma Recurrence—Data from a Randomized Clinical Trial , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[58] P. Roderick,et al. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. , 1993, British journal of clinical pharmacology.
[59] L. Perdue,et al. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. , 2022, JAMA.
[60] Susan Halabi,et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.
[61] L. Chew,et al. Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. , 2014, Anticancer research.
[62] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[63] W. Zheng,et al. Urinary Prostaglandin E2 Metabolite and Risk for Colorectal Adenoma , 2011, Cancer Prevention Research.
[64] A. Algra,et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.
[65] Á. Lanas,et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[66] P. Rothwell,et al. Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview , 2011, Cancer Prevention Research.
[67] S. Narumiya,et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.
[68] R. Murphy,et al. The role of PGE2 in intestinal inflammation and tumorigenesis. , 2015, Prostaglandins & other lipid mediators.
[69] C. Ulrich,et al. Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1 , 2012, Pharmacogenetics and genomics.
[70] J. Morrow,et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. , 2004, Analytical biochemistry.
[71] E. Rimm,et al. Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.
[72] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[73] Ross J. Harris,et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis , 2009, Cancer Causes & Control.
[74] R. Armstrong,et al. Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1. , 2011, Biochemistry.
[75] E. Giovannucci,et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. , 2014, Journal of the National Cancer Institute.
[76] Molin Wang,et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. , 2013, JAMA.
[77] C. Patrono,et al. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. , 2015, Biochimica et biophysica acta.
[78] D. Rosenberg,et al. mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". , 2010, Biochimie.
[79] Rajnish A. Gupta,et al. Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.
[80] K. Druey,et al. Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.
[81] L. Laine,et al. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.
[82] K. Kinzler,et al. PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.
[83] B. Rigas,et al. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis. , 2006, Carcinogenesis.
[84] J. Hurley,et al. The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.
[85] J. Baron,et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.
[86] J. Gaziano,et al. Low-Dose Aspirin in the Primary Prevention of Cancer. The Women’s Health Study: A Randomized Controlled Trial , 2005 .
[87] Stephen Senn,et al. Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials , 2013, Drugs in R&D.
[88] Y. Loke,et al. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis , 2000, BMJ : British Medical Journal.
[89] E. Giovannucci,et al. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD) , 2014, Science Translational Medicine.
[90] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[91] K. Muir,et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. , 2008, Gastroenterology.
[92] Edward S. Kim,et al. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial , 2008, Cancer Prevention Research.
[93] S. Narumiya,et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. , 1999, Cancer research.
[94] J. Potter,et al. Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial , 2015, BMC Medical Genetics.
[95] R. Pearson. Inflammatory Markers Are Associated With Risk of Colorectal Cancer and Chemopreventive Response to Anti-Inflammatory Drugs , 2011 .
[96] Deepak L. Bhatt,et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. , 2005, The American journal of cardiology.
[97] J. Bigby,et al. Goodman and Gillman's The Pharmacological Basis of Therapeutics , 1992 .
[98] B. Leggett,et al. The serrated pathway to colorectal carcinoma: current concepts and challenges , 2013, Histopathology.
[99] David Reich,et al. A common genetic risk factor for colorectal and prostate cancer , 2007, Nature Genetics.
[100] M. Gala,et al. Genetics of the Serrated Pathway to Colorectal Cancer , 2015, Clinical and Translational Gastroenterology.
[101] P. Rothwell,et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.
[102] L. Zon,et al. Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration , 2009, Cell.
[103] Reiko Nishihara,et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.
[104] E. Giovannucci,et al. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. , 2011, Gastroenterology.
[105] J. Willis,et al. Inactivating Mutation in the Prostaglandin Transporter Gene, SLCO2A1, Associated with Familial Digital Clubbing, Colon Neoplasia, and NSAID Resistance , 2014, Cancer Prevention Research.
[106] D. Alberts,et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[107] D. Richel,et al. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A , 2006, Oncogene.
[108] T. P. Pretlow,et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis , 2006, Proceedings of the National Academy of Sciences.
[109] J. Little,et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. , 2003, Gastroenterology.
[110] H. Pommergaard,et al. Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. , 2016, Gastroenterology.
[111] J. Zell,et al. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. , 2010, Journal of the National Cancer Institute.
[112] B. Yawn,et al. Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2007, Annals of Internal Medicine.
[113] R. DuBois,et al. Urinary PGE-M: A Promising Cancer Biomarker , 2013, Cancer Prevention Research.
[114] Shuji Ogino,et al. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.
[115] D. D. Billheimer,et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[116] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[117] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[118] S. Kudo,et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial , 2014, Gut.
[119] Oliver Sieber,et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 , 2007, Nature Genetics.
[120] L F Watson,et al. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.
[121] Elizabeth L. Barry,et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. , 2006, Journal of the National Cancer Institute.
[122] Elizabeth L. Barry,et al. Variants Downstream of the Ornithine Decarboxylase Gene Influence Risk of Colorectal Adenoma and Aspirin Chemoprevention , 2011, Cancer Prevention Research.
[123] N. Cook,et al. Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.
[124] K. Schrör. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. , 2011, Best practice & research. Clinical gastroenterology.
[125] G. S. Ranger. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. , 2014, Anticancer research.
[126] Jacques Van Dam,et al. Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions , 2015, Clinical Cancer Research.
[127] J. Hamilton,et al. The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism , 2011, Growth factors.
[128] M. Gala,et al. Molecular Pathways: Aspirin and Wnt Signaling—A Molecularly Targeted Approach to Cancer Prevention and Treatment , 2014, Clinical Cancer Research.
[129] R. DuBois,et al. The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.
[130] P. Rothwell,et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.
[131] N. Habermann,et al. Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[132] A. Montgomery,et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial , 2013, Trials.
[133] T. Hartman,et al. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions , 2014, Genes, chromosomes & cancer.
[134] J. Barrett,et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPAR&ggr; act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma , 2005, Pharmacogenetics and genomics.
[135] F. Sinicrope,et al. Aspirin and Colorectal Cancer: Back to the Future , 2013, Clinical Cancer Research.
[136] Young-Joon Kim,et al. Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[137] J. Cuzick,et al. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population , 2014, European Journal of Epidemiology.
[138] Aung Ko Win,et al. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry , 2014, Genes, chromosomes & cancer.
[139] S. Dey,et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ , 2004 .
[140] R. Langenbach,et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.
[141] G. Casey,et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. , 2009, World journal of gastroenterology.
[142] David A. Drew,et al. Colorectal polyp prevention by daily aspirin use is abrogated among active smokers , 2015, Cancer Causes & Control.
[143] T. Eide,et al. Natural history of adenomas , 2005, World Journal of Surgery.
[144] C. Carlson,et al. Polymorphisms predicted to alter function in Prostaglandin E2 synthase and Prostaglandin E2 receptors , 2007, Pharmacogenetics and genomics.
[145] Peter Kraft,et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. , 2013, Journal of the National Cancer Institute.
[146] J. Meyerhardt,et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. , 2015, Journal of the National Cancer Institute.
[147] M. Schuler. Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.
[148] S. Ogino,et al. Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .
[149] Laura K. Bianchi,et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin , 2015, Gut.
[150] Miki Ohira,et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. , 2005, Cancer research.
[151] R. Wender. Aspirin and NSAID chemoprevention, gene-environment interactions, and risk of colorectal cancer. , 2015, JAMA.
[152] Vadim Backman,et al. Association between rectal optical signatures and colonic neoplasia: potential applications for screening. , 2009, Cancer research.
[153] E. Gerner,et al. Combination Chemoprevention for Colon Cancer Targeting Polyamine Synthesis and Inflammation , 2009, Clinical Cancer Research.
[154] N. Rothman,et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] Charles J. Kahi,et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.
[156] G. Thomas,et al. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. , 1994, Gut.
[157] M. Rawlins,et al. Prophylactic aspirin and risk of peptic ulcer bleeding , 1995, BMJ.